The University of Michigan
412 Maynard
Ann Arbor, MI 48109-1399

Feb. 24, 1999 (26)
Contact: Sally Pobojewski [email protected] 734-647-1844

Interleukin-2 boosts effectiveness of U-M cancer vaccine in mice. Phase II human trials may begin this summer.

EDITORS: Color photographs of lungs from experimental and control mice used in the U-M study are available on request. This news release with the grphics/pictures can be found at

TYPE OF ARTICLE
Research Results
SECTION
KEYWORDS
Interleukin 2 Cancer Vaccine Sarcomas Melanomas
COMMENTS | COMMENTING POLICY